Welcome to our dedicated page for Modular Medical SEC filings (Ticker: MODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Modular Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Modular Medical's regulatory disclosures and financial reporting.
Modular Medical, Inc. (Nasdaq: MODD) has filed its Form 10-K for the fiscal year ended March 31, 2025. The filing confirms that the Nevada-incorporated diabetes-focused medical device company remains a non-accelerated filer, smaller reporting company, and is not an emerging growth company. The report was filed on a timely basis and the registrant affirms that all required reports and interactive data files have been submitted during the preceding 12 months.
Capital structure and market data: as of June 16, 2025, the company had 54,247,388 shares of common stock outstanding. The aggregate market value of shares held by non-affiliates was $62.27 million based on the September 30, 2024 Nasdaq closing price.
The 10-K outlines a full set of standard disclosures, including risk factors (Item 1A), management’s discussion & analysis (Item 7), and financial statements (Item 8), but detailed revenue, earnings and cash-flow figures are not included in the excerpt provided. A lengthy Special Note Regarding Forward-Looking Statements lists more than a dozen risk considerations, mainly centred on:
- Obtaining FDA clearances for its insulin pump products.
- Financing needs and liquidity horizon.
- Competition from larger diabetes device manufacturers.
- Protection of intellectual property.
- Ability to hire and retain key personnel.
The company confirms it is not a shell company and that no restatement-triggering error corrections were included in the financials. No attestations under SOX 404(b) were provided, consistent with non-accelerated filer status.
Overall, the filing is largely procedural and centres on forward-looking risk disclosures rather than new financial performance metrics or strategic transactions.